Drug intelligence / Profile preview

AXT-2003

Development stage: Preclinical
Lead developer: Axter Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

AXT-2003 is a preclinical-stage small molecule combination therapy being developed by Axter Therapeutics for the treatment of prostate cancer. The drug candidate combines an EZH2 (Enhancer of zeste homolog 2) inhibitor with an androgen receptor (AR) inhibitor. This dual-mechanism approach aims to suppress complementary growth pathways in prostate cancer cells, potentially addressing resistance to standard androgen deprivation therapies. EZH2 is an epigenetic enzyme that promotes cancer progression and lineage plasticity, while the androgen receptor is the primary driver of prostate cancer growth.

Targets

EZH2 (Histone-lysine N-methyltransferase EZH2)AR (Adrenergic receptors)

Beyond the preview

Go deeper on AXT-2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXT-2003.

Explore the full profile